Option chain shows key data for Ipsen's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Ipsen.

Ipsen (OTC:IPSEY) Stock, Option Chain

IPSEN S.A. ADR

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Equities

News

Health Care

Media

General

GNFT

IPSEF

IPSEY

The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug&#39;s ability to reduce alkaline phosphatase levels, marks a significant advancement in therapies available for PBC.

FDA Fast-Tracks Ipsen And Genfit&#39;s New Liver Disease Treatment, Iqirvo

Biotech

Trading Ideas

EXEL

RHHBF

RHHBY

RHHVF

Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&amp;nbs

Third Time Lucky: Exelixis&#39; Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients

Analyst Color

Penny Stocks

Small Cap

Analyst Ratings

Movers

CBAY

Friday, CymaBay Therapeutics Inc&#39;s (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC: 

Genfit&#39;s Miss Is CymaBay Therapeutics&#39; Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class

Ipsen SA

Press Releases

Ipsen's Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

Ipsen receives its second Shingo Prize for operational excellence

Earnings

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

Ipsen announces issuance of €500 million inaugural Rated Public Bond

PARIS:IPN

Ipsen

Comments

Ipsen

Ipsen (IPSEY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga